Last reviewed · How we verify

Cinobufacini Injection — Competitive Intelligence Brief

Cinobufacini Injection (Cinobufacini Injection) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Natural product bufadienolide; cardiac glycoside analog. Area: Oncology.

marketed Natural product bufadienolide; cardiac glycoside analog Na+/K+-ATPase; multiple apoptotic pathways Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Cinobufacini Injection (Cinobufacini Injection) — Dongfang Hospital Beijing University of Chinese Medicine. Cinobufacini is a bufadienolide compound derived from toad venom that inhibits cell proliferation and induces apoptosis in cancer cells through multiple pathways.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Cinobufacini Injection TARGET Cinobufacini Injection Dongfang Hospital Beijing University of Chinese Medicine marketed Natural product bufadienolide; cardiac glycoside analog Na+/K+-ATPase; multiple apoptotic pathways

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Natural product bufadienolide; cardiac glycoside analog class)

  1. Dongfang Hospital Beijing University of Chinese Medicine · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Cinobufacini Injection — Competitive Intelligence Brief. https://druglandscape.com/ci/cinobufacini-injection. Accessed 2026-05-15.

Build your own brief

Pick any drug + add comparators: